Financial Services Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,829
Closed -$606K – 91
2026
Q2
$606K Buy
+3,829
New +$518K 0.15% 53
2026
Q1
– Sell
-6,984
Closed -$852K – 77
2025
Q4
$852K Buy
+6,984
New +$801K 0.31% 41
2023
Q3
– Sell
-9,610
Closed -$800K – 57
2023
Q2
$800K Buy
+9,610
New +$804K 0.33% 31

Other funds holding XBI

Financial Services Advisory's XBI Position: Q3 2026 in Review

Financial Services Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2026, closing a stake of 3,829 shares — an estimated $606K sold.

Financial Services Advisory first reported a position in XBI in Q2 2023 and held it in 3 quarters. The position peaked at $852K in Q4 2025. 959 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Financial Services Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2026 after selling out during the quarter.
  • Financial Services Advisory sold 3,829 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $606K.
  • Financial Services Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q2 2023 and held it in 3 quarters.
  • Financial Services Advisory's State Street SPDR S&P Biotech ETF position peaked at $852K in Q4 2025.
  • 959 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Financial Services Advisory's 13F filing for Q3 2026, filed 26 Oct 2026.